Viewing Study NCT05195632


Ignite Creation Date: 2025-12-24 @ 9:56 PM
Ignite Modification Date: 2026-01-02 @ 4:05 AM
Study NCT ID: NCT05195632
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-06-22
First Post: 2022-01-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
Sponsor: Pierre Fabre Medicament
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Encorafenib View
None Binimetinib View
None Lung Cancer View
None BRAF-inhibitor View
None MEK-inhibitor View
None BRAF V600E -mutated Chinese patients View
None Non-Small Cell Lung Cancer View